196 related articles for article (PubMed ID: 36241535)
1. Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study.
Livne-Margolin M; Ling D; Attia-Konyo S; Abitbol CM; Haj-Natour O; Ungar B; Ben-Horin S; Kopylov U
Dig Liver Dis; 2023 Feb; 55(2):223-229. PubMed ID: 36241535
[TBL] [Abstract][Full Text] [Related]
2. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
Tadbiri S; Peyrin-Biroulet L; Serrero M; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Gilletta C; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Fumery M; Claudepierre P; Bouhnik Y; Amiot A;
Aliment Pharmacol Ther; 2018 Feb; 47(4):485-493. PubMed ID: 29250803
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort Study.
De Galan C; Truyens M; Peeters H; Mesonero Gismero F; Elorza A; Torres P; Vandermeulen L; Amezaga AJ; Ferreiro-Iglesias R; Holvoet T; Zabana Y; Reverter LP; Gonzales GB; Geldof J; Varkas G; De Vos M; Lobatón T
J Crohns Colitis; 2022 Nov; 16(11):1676-1686. PubMed ID: 35442433
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients.
Gebeyehu GG; Fiske J; Liu E; Limdi JK; Broglio G; Selinger C; Razsanskaite V; Smith PJ; Flanagan PK; Subramanian S
Dig Dis Sci; 2023 May; 68(5):1983-1994. PubMed ID: 36436155
[TBL] [Abstract][Full Text] [Related]
5. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
[TBL] [Abstract][Full Text] [Related]
6. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors.
Onali S; Pugliese D; Caprioli FA; Orlando A; Biancone L; Nardone OM; Imperatore N; Fiorino G; Cappello M; Viola A; Principi MB; Bezzio C; Aratari A; Carparelli S; Mazzuoli S; Manguso F; Grossi L; Bodini G; Ribaldone D; Mocci G; Miranda A; Minerba L; Favale A; Grova M; Scucchi L; Segato S; Fries W; Castiglione F; Armuzzi A; Fantini MC;
Am J Gastroenterol; 2022 Aug; 117(8):1279-1287. PubMed ID: 35467558
[TBL] [Abstract][Full Text] [Related]
7. Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
Singh S; Kim J; Luo J; Paul P; Rudrapatna V; Park S; Zheng K; Syal G; Ha C; Fleshner P; McGovern D; Sauk JS; Limketkai B; Dulai PS; Boland BS; Eisenstein S; Ramamoorthy S; Melmed G; Mahadevan U; Sandborn WJ; Ohno-Machado L
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2359-2369.e5. PubMed ID: 36343846
[TBL] [Abstract][Full Text] [Related]
8. Comparison of surgery rates in biologic-naïve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN.
Vu M; Ghosh S; Umashankar K; Weber L; Landis C; Candela N; Chastek B
BMC Gastroenterol; 2023 Mar; 23(1):87. PubMed ID: 36966279
[TBL] [Abstract][Full Text] [Related]
9. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
Ibing S; Cho JH; Böttinger EP; Ungaro RC
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2629-2638. PubMed ID: 36787837
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study).
Alrashed F; Abdullah I; Alfadhli A; Shehab M
Front Pharmacol; 2023; 14():1243080. PubMed ID: 37876726
[No Abstract] [Full Text] [Related]
12. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab.
Dupré A; Collins M; Nocturne G; Carbonnel F; Mariette X; Seror R
Rheumatology (Oxford); 2020 Nov; 59(11):3275-3283. PubMed ID: 32259251
[TBL] [Abstract][Full Text] [Related]
13. Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
Blesl A; Petritsch W; Binder L; Fürst S; Wenzl H; Baumann-Durchschein F; Kump P; Högenauer C
Scand J Gastroenterol; 2022 Nov; 57(11):1327-1330. PubMed ID: 35732583
[TBL] [Abstract][Full Text] [Related]
14. Risk of infection in elderly patients with inflammatory bowel disease under biologics: A prospective, multicenter, observational, one-year follow-up comparative study.
Bozon A; Nancey S; Serrero M; Caillo L; Gilletta C; Benezech A; Combes R; Danan G; Akouete S; Pages L; Bourgaux JF; Le Cosquer G; Boivineau L; Meszaros M; Altwegg R
Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102107. PubMed ID: 36906225
[TBL] [Abstract][Full Text] [Related]
15. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
[TBL] [Abstract][Full Text] [Related]
16. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.
Narula N; Aruljothy A; Wong ECL; Homenauth R; Alshahrani AA; Marshall JK; Reinisch W
United European Gastroenterol J; 2021 Jun; 9(5):581-589. PubMed ID: 34077627
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy.
Hong SJ; Zenger C; Pecoriello J; Pang A; Vallely M; Hudesman DP; Chang S; Axelrad JE
Inflamm Bowel Dis; 2022 Dec; 28(12):1826-1832. PubMed ID: 35262671
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease.
Lutz M; Caldera F; Schroeder K; Gazis D; Crawford JM; Long MD; Barnes EL
Clin Transl Gastroenterol; 2023 Nov; 14(11):e00620. PubMed ID: 37450671
[TBL] [Abstract][Full Text] [Related]
19. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
Barré A; Colombel JF; Ungaro R
Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
